Contrasting Effects of the γ-Aminobutyric Acid Type A Receptor β3 Subunit N265M Mutation on Loss of Righting Reflexes Induced by Etomidate and the Novel Anesthetic Barbiturate R–mTFD-MPAB: Erratum

    loading  Checking for direct PDF access through Ovid

Excerpt

The article, “Contrasting Effects of the γ-Aminobutyric Acid Type A Receptor β3 Subunit N265M Mutation on Loss of Righting Reflexes Induced by Etomidate and the Novel Anesthetic Barbiturate R–mTFD-MPAB,” which appeared in the November 2016 issue of Anesthesia & Analgesia, contained errors.
First, the x-axis of figure 2b is incorrectly labeled “etomidate dose (mg/kg)” when it should be “R-mTFD-MPAB dose (mg/kg).”
Secondly, the second sentence of the fourth paragraph in the Results section reads: “The 2.5, 5, and 10 mg/kg doses yielded median RORR times of [137.75], 348 [157], and 926 [20] seconds, respectively.” The number “113.5” is omitted. The sentence should read “The 2.5, 5, and 10 mg/kg doses yielded median RORR times of 113.5 [137.75], 348 [157], and 926 [20] seconds, respectively.”
The third paragraph of the Methods section states that etomidate was dissolved in sterile saline. This is incorrect. The sentence should read “Etomidate (Tocris Bioscience, Bristol, UK) was dissolved in dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO) to 5mg/ml stock solution.”
The authors and publishers regret these errors.
    loading  Loading Related Articles